These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 18626964)

  • 41. Expression and Clinical Significance of Elafin in Inflammatory Bowel Disease.
    Zhang W; Teng G; Wu T; Tian Y; Wang H
    Inflamm Bowel Dis; 2017 Dec; 23(12):2134-2141. PubMed ID: 29084078
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prevalence, significance and predictive value of antiphospholipid antibodies in Crohn's disease.
    Sipeki N; Davida L; Palyu E; Altorjay I; Harsfalvi J; Szalmas PA; Szabo Z; Veres G; Shums Z; Norman GL; Lakatos PL; Papp M
    World J Gastroenterol; 2015 Jun; 21(22):6952-64. PubMed ID: 26078573
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Correlation between serological biomarkers and endoscopic activity in patients with inflammatory bowel disease.
    Miranda-García P; Chaparro M; Gisbert JP
    Gastroenterol Hepatol; 2016 Oct; 39(8):508-15. PubMed ID: 27020243
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fragments of Citrullinated and MMP-degraded Vimentin and MMP-degraded Type III Collagen Are Novel Serological Biomarkers to Differentiate Crohn's Disease from Ulcerative Colitis.
    Mortensen JH; Godskesen LE; Jensen MD; Van Haaften WT; Klinge LG; Olinga P; Dijkstra G; Kjeldsen J; Karsdal MA; Bay-Jensen AC; Krag A
    J Crohns Colitis; 2015 Oct; 9(10):863-72. PubMed ID: 26188349
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Profiles of Lamina Propria T Helper Cell Subsets Discriminate Between Ulcerative Colitis and Crohn's Disease.
    Li J; Ueno A; Fort Gasia M; Luider J; Wang T; Hirota C; Jijon HB; Deane M; Tom M; Chan R; Barkema HW; Beck PL; Kaplan GG; Panaccione R; Qian J; Iacucci M; Gui X; Ghosh S
    Inflamm Bowel Dis; 2016 Aug; 22(8):1779-92. PubMed ID: 27243594
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inflammatory bowel disease activity assessment with biologic markers and 99mTc-WBC scintigraphy: are there different trends in ileitis versus colitis?
    Charron M
    J Nucl Med; 2003 Oct; 44(10):1586-91. PubMed ID: 14530471
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Oversecretion and Overexpression of Nicotinamide Phosphoribosyltransferase/Pre-B Colony-Enhancing Factor/Visfatin in Inflammatory Bowel Disease Reflects the Disease Activity, Severity of Inflammatory Response and Hypoxia.
    Neubauer K; Bednarz-Misa I; Walecka-Zacharska E; Wierzbicki J; Agrawal A; Gamian A; Krzystek-Korpacka M
    Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30621173
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
    Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
    Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of Ischemia-Modified Albumin in Patients with Inflammatory Bowel Disease.
    Guntas G; Sahin A; Duran S; Kahraman R; Duran I; Sonmez C; Calhan T; Sokmen HM
    Clin Lab; 2017 Feb; 63(2):341-347. PubMed ID: 28182340
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Paraoxonase 1 activity and level of antibodies directed against oxidized low density lipoproteins in a group of an elderly population in Poland - PolSenior study.
    Bednarska-Makaruk M; Rodo M; Szirkowiec W; Mossakowska M; Puzianowska-Kuźnicka M; Skalska A; Zdrojewski T; Ryglewicz D; Wehr H
    Arch Gerontol Geriatr; 2015; 60(1):153-61. PubMed ID: 25459919
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Paraoxonase 1 (PON1) status in gastroesophageal malignancies and associated paraneoplastic syndromes - connection with inflammation.
    Krzystek-Korpacka M; Boehm D; Matusiewicz M; Diakowska D; Grabowski K; Gamian A
    Clin Biochem; 2008 Jul; 41(10-11):804-11. PubMed ID: 18423402
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serum Visfatin as a Diagnostic Marker of Active Inflammatory Bowel Disease.
    Saadoun MM; Nosair NAE; Abdel-Azeez HA; Sharaf SM; Ahmed MH
    J Gastrointestin Liver Dis; 2021 Sep; 30(3):339-345. PubMed ID: 34551033
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Crohn's-like clinical and pathological manifestations of giant inflammatory polyposis in IBD: a potential diagnostic pitfall.
    Naymagon S; Mikulasovich M; Gui X; Ullman TA; Harpaz N
    J Crohns Colitis; 2014 Jul; 8(7):635-40. PubMed ID: 24368253
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Serum inter-alpha-trypsin inhibitor heavy chain 4 in patients with inflammatory bowel disease: correlation with disease risk, inflammation, activity, and its variation after treatment.
    Wen N; Zhao N; Xu H; Zhao Y; Ma J
    Ir J Med Sci; 2022 Oct; 191(5):2105-2111. PubMed ID: 34843071
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Serum prohepcidin levels in chronic inflammatory bowel diseases.
    Nagy J; Lakner L; Poór VS; Pandur E; Mózsik G; Miseta A; Sipos K
    J Crohns Colitis; 2010 Dec; 4(6):649-53. PubMed ID: 21122575
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers.
    Ricanek P; Brackmann S; Perminow G; Lyckander LG; Sponheim J; Holme O; Høie O; Rydning A; Vatn MH;
    Scand J Gastroenterol; 2011 Sep; 46(9):1081-91. PubMed ID: 21619483
    [TBL] [Abstract][Full Text] [Related]  

  • 57. LINC00641/miR-378a and Their Cross-Talk with TNF-α/IFN-γ as Potential Biomarkers in Ulcerative Colitis and Crohn's Diseases.
    Hameed NAA; Shaker OG; Hasona NA
    J Interferon Cytokine Res; 2023 Nov; 43(11):531-537. PubMed ID: 37956249
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Correlation of serum-soluble triggering receptor expressed on myeloid cells-1 with clinical disease activity in inflammatory bowel disease.
    Park JJ; Cheon JH; Kim BY; Kim DH; Kim ES; Kim TI; Lee KR; Kim WH
    Dig Dis Sci; 2009 Jul; 54(7):1525-31. PubMed ID: 18975078
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Activity of paraoxonase 1 (PON1) and its relationship to markers of lipoprotein oxidation in healthy Slovaks.
    Sumegová K; Blazícek P; Waczulíková I; Zitnanová I; Duracková Z
    Acta Biochim Pol; 2006; 53(4):783-7. PubMed ID: 17106515
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Imbalance between interleukin-1 agonists and antagonists: relationship to severity of inflammatory bowel disease.
    Ludwiczek O; Vannier E; Borggraefe I; Kaser A; Siegmund B; Dinarello CA; Tilg H
    Clin Exp Immunol; 2004 Nov; 138(2):323-9. PubMed ID: 15498044
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.